Real-World Study Shows Trastuzumab Deruxtecan Improves Five-Year Survival in HER2-Positive Metastatic Colorectal Cancer
核心洞察
A retrospective study of 11,112 patients demonstrates that trastuzumab deruxtecan (T-DXd/Enhertu) achieves 58% five-year overall survival compared to 49% with standard chemotherapy in HER2-positive metastatic colorectal cancer (搜索).
The targeted antibody-drug conjugate showed particular benefit when used earlier in treatment as second-line therapy, with manageable safety profile in real-world clinical practice.
These findings validate clinical trial results in everyday cancer care settings and suggest T-DXd may offer meaningful survival advantages for patients with this aggressive disease subtype.
A large real-world study has demonstrated that trastuzumab deruxtecan (T-DXd, Enhertu) significantly extends long-term survival in patients with HER2-positive metastatic colorectal cancer (搜索) compared to standard chemotherapy. The retrospective analysis of 11,112 patients showed a five-year overall survival rate of 58% for those treated with the targeted therapy versus 49% for patients receiving standard chemotherapy.
The findings, presented by researchers from Roswell Park Comprehensive Cancer Center at the 2026 American Association for Cancer Research (AACR) annual meeting in San Diego, provide crucial evidence that the survival benefits observed in clinical trials translate to real-world clinical practice.
Addressing an Aggressive Disease with Limited Treatment Options
HER2-positive metastatic colorectal cancer (搜索) represents an aggressive disease subtype that often shows limited response to standard chemotherapy. While clinical trials have demonstrated that trastuzumab deruxtecan can prolong overall survival, its effectiveness outside the controlled environment of clinical trials remained unclear until now.
"Our study suggests that T-DXd may improve long-term survival when used earlier in treatment, with manageable real-world safety," explains Zunairah Shah, MBBS, co-first author of the study and Hematology/Oncology Fellow at Roswell Park.
Comprehensive Real-World Analysis
The research team analyzed data from 11,112 patients, including 9,135 treated with standard chemotherapy and 1,977 treated with T-DXd. The study specifically examined outcomes when T-DXd was used in the second-line setting, representing earlier intervention compared to its typical use in third-line therapy or beyond.
Trastuzumab deruxtecan is an antibody-drug conjugate that delivers chemotherapy directly to cancer cells overexpressing the HER2 (搜索) protein while bypassing healthy cells. This targeted approach has shown promise across multiple tumor types, with antibody-drug conjugates demonstrating greater benefit when used earlier in treatment courses.
Long-Term Survival Benefits
While overall survival rates were similar between the two treatment groups at one year, the advantage of T-DXd became apparent over time. At five years, patients treated with the targeted therapy achieved a 58% overall survival rate compared with 49% in the standard chemotherapy group.
"In this study, trastuzumab deruxtecan was associated with improved long-term survival compared with standard chemotherapy, along with a lower risk of death and a manageable safety profile," says Dr. Shah. "These findings suggest it may offer a meaningful benefit for patients with HER2-positive metastatic colorectal cancer (搜索), improving outcomes in this aggressive disease."
Clinical Implications and Future Directions
The study's co-senior author, Kannan Thanikachalam, MD, Assistant Professor of Gastrointestinal Medical Oncology at Roswell Park, emphasized both the promise and limitations of the findings. "While trastuzumab deruxtecan has typically been used in advanced colorectal cancer (搜索) in later lines of therapy — third line or beyond — this retrospective real-world study shows that patients had improved survival outcomes if T-DXd was used earlier in patients with HER2 (搜索)-positive colorectal cancer," he noted.
However, Dr. Thanikachalam cautioned that "prospective clinical trials are needed to validate these findings. Pulmonary toxicity will also need to be considered in patients who receive T-DXd."
Broader Treatment Strategy Implications
The results align with similar findings in other cancer types, particularly HER2 (搜索)-positive metastatic breast cancer (搜索). Sheheryar Kabraji, BMBCh, Chief of Breast Medicine and Director of Breast Translational Research at Roswell Park and co-senior author of the study, noted the consistency across tumor types.
"Results from this study are strikingly similar to trial data from HER2 (搜索)-positive metastatic breast cancer (搜索) showing preserved or improved efficacy of trastuzumab deruxtecan when used in earlier lines," says Dr. Kabraji. "This work is an important example of how clinicians can use real-world data to optimize therapies for an aggressive cancer like HER2-positive colorectal disease."
The research represents a significant step toward more precise, evidence-based treatment strategies that could ultimately improve patient outcomes in this challenging cancer subtype. The findings were presented as Abstract 1303 during the AACR meeting, highlighting the growing importance of real-world evidence in validating and optimizing cancer therapies.